Sabby Management LLC has recently announced that it has increased stake in Baudax Bio Inc. (NASDAQ:BXRX) by 832.19%. After grabbing 0.44 million shares, the institutional investor is now in possession of 0.39 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.20% having worth around $89601.0. Moreover, Warberg Asset Management LLC increased its share by 0.24 million to have a control over 0.27 million shares. And Virtu Financial BD LLC raised its holdings to 87828.0 shares by acquiring 0.11 million shares or 0.54% of the stake.
Baudax Bio Inc. (BXRX) concluded trading on 11/30/22 at a closing price of $0.15, with 6.96 million shares of worth about $1.04 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -81.70% during that period and on Wednesday the price saw a gain of about 4.45%. Currently the company’s common shares owned by public are about 20.00M shares, out of which, 19.94M shares are available for trading.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the BXRX stock and their offered price forecasts bring an average price target of $0.60. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $0.60 and could fall to a lowest price of $0.60. However, touching the estimated high of $0.60 would mean a gain of 75.0% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 6 times over the past 12 months. They bought 212,832 shares in 6 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Nasdaq Composite Index F are the top 3 mutual funds which are holding stakes in Baudax Bio Inc. Vanguard Extended Market Index Fu is currently holding 58320.0 shares of worth totaling $11897.0. The company recently came buying 0.0 shares which brought its stake up to 0.29% of the company’s outstanding shares. Fidelity Nasdaq Composite Index F, after buying 17792.0 shares, have now control over 0.09% of the stake in the company. It holds 0.0 shares of worth $3630.0.
Baudax Bio Inc. (NASDAQ: BXRX) started trading at $5.92, above $5.78 from concluding price of the previous day. However, the stock later moved at a day high price of 0.1900, or with a gain of 4.45%. Stock saw a price change of 3.93% in past 5 days and over the past one month there was a price change of -28.78%. Year-to-date (YTD), BXRX shares are showing a performance of -98.10% which decreased to -98.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.12 but also hit the highest price of $14.18 during that period. The average intraday trading volume for Baudax Bio Inc. shares is 1.57 million. The stock is currently trading -7.43% below its 20-day simple moving average (SMA20), while that difference is down -27.01% for SMA50 and it goes to -85.56% lower than SMA200.
Sabby Management LLC acquired 0.44 million shares of Baudax Bio Inc. having value of about $89601.0. Data submitted at the U.S SEC by Sabby Management LLC revealed that the firm now holds 0.39 million shares in the company valued at close to $58815.45, or have control over 832.19% stake in the company. Baudax Bio Inc. (NASDAQ: BXRX) currently have 20.00M outstanding shares and institutions hold larger chunk of about 7.30% of that. Holding of mutual funds in the company is about 1.41% while other institutional holders and individual stake holders have control over 6.56% and 0.62% of the stake respectively.
The stock has a current market capitalization of $2.73M. PE ratio of stock for trailing 12 months is 0.03, while it has posted earnings per share of $4.50 in the same period. It has Quick Ratio of 0.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BXRX, volatility over the week remained 24.19% while standing at 16.26% over the month.
Analysts are in expectations that Baudax Bio Inc. (BXRX) stock would likely to be making an EPS of -$0.53 in the current quarter, while forecast for next quarter EPS is -$0.26 and it is -$0.51 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.53 which is -$0.53 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$7 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 92.60% while it is estimated to increase by 94.90% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Baudax Bio Inc. (BXRX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on May 15, 2020 offering a Mkt outperform rating for the stock and assigned a target price of $13 to it.
